Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 3
---
) 5 1,211 Employees 6 Lake Forest, CA Headquarters ▪ STAAR Surgical designs, develops, manufactures and sells Implantable Collamer® Lenses (ICLs) for refractive surgery to treat myo pia (near - sightedness) — Myopia is the most common ocular disorder in the world, affecting ~2.6 billion people – a number that is projected to approximat ely double by 2050 7 ▪ STAAR’s EVO ICL technology competes with other refractive surgery treatments, including LASIK, PRK and SMILE — STAAR’s EVO ICLs offer many advantages over these treatments, including a lower likelihood of dry eye, a short recovery time, re movability and UV protection — STAAR’s ICLs have been gaining traction in many countries where the Company has been taking market share from other refractiv e p rocedures; in Japan, for example, STAAR’s market share is over 70% ▪ STAAR is a fundamentally sound company with a bright future — The Company has nearly $200 million in cash, no debt, leading technology, a privileged position in large markets and a clear pat h to growth and profit margin expansion in the near term >2M >2.5M >3M 2022 2023 2024 Number of STAAR ICLs Sold to Date 1 STAAR ICL Market Share by Geography 2 Summary Data 4 73% 18% 17% 15% 15% 8% 4% Japan China³ South Korea Global Spain Germany U.S.

Broadwood Partners, L.P. Overview of Alcon (SIX/NYSE: ALC) 6 1. Source: Alcon Press Releases, August 19, 2025, May 13, 2025, February 25, 2025 and November 12, 2024. 2. Source: FactSet. Data as of September 23, 2025. 3. Source: Alcon Annual Report on Form 20 - F, filed with the SEC on February 25, 2025. Alcon is a global leader in eye care with a broad portfolio of products $41,607 Enterprise Value ($M) 2 $38,277 Market Value ($M) 2 $4,745 Total Debt ($M) 1 $1,415 Cash and Equivalents ($M) 1 $9